Neoadjuvant chemotherapy of gastric cancer with oral UFT (a mixture of uracil and fturafur) during the waiting period for surgery

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 523-530

  Nio, Yoshinori ^a   Sato, Yoshitoshi ^a   Nagami, Haruhiko ^a   Teramoto, Makoto ^a   Inoue, Yasusi ^a   Yano, Seiji ^a   Sumi, Shoichiro ^a   Tamura, Katsuhiro ^a   Fukumoto, Manabu ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Neoadjuvant chemotherapy; UFT

Indexed keywords

PYRIMIDINE ANTAGONIST; TEGAFUR; UFT; URACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; FEMALE; GASTRECTOMY; HUMAN; LIVER DYSFUNCTION; MALE; ORAL DRUG ADMINISTRATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH CANCER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TEGAFUR; URACIL;

EID: 0031899554     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wagener DJT, Yap SH, Wobbes T, et al: Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86-87, 1985.
2. Moertel CG, Rubin J, O' Connel MJ et al: A phase II trial of 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053-1057, 1986.
3. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
4. Spalano JA, Schwartz EL, Salva KM, et al: Phase II trial of etoposide, doxorubicin (adriamycin) and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol (CCT) 13: 374-378, 1990.
5. Stephens FO, Adams BG, Crea P, et al: Intra-arterial chemotherapy given preoperatrvely in the management of carcinoma of the stomach. Surg Gynecol Obstet 162: 370-374, 1986.
6. Wilke H, Preusser U, Gunzer U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J ClinOncol7:1318-1326, 1989.
7. Yonemura Y, Sawa T, Kinoshita K, et al: Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17: 256-262, 1993.
8. Arima S, Ohsato K, Hisatsugu T, et al: Multicenterrandomized study of adjuvant chemotherapy with mitomycin-C and tegafur or tegafururacil in gastric cancer. Eur J Surg 160: 227-232, 199A.
9. The Study group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer. Eur J Surg Oncol 21: 69-77, 1995.
10. Ikeda K, Saitoh S, Koide I, et al: A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol (CCT) 18: 204-210, 1995.
11. Ikenaka K, Shirasaka T, Kitano S, et al: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70: 353-359, 1979.
12. Unemi N and Takeda S: Studies on combination therapy with 1-(tetrahydro-2- furanyl) -5-fluorouracil plus uracil. II. Effect of uracil on in vitro metabolism of 1-(tetrahydro-2- furanyl)-5-fluorouracil. Chemotherapy 29: 176-184, 1981.
13. Fujii S, Kitano S, Ikenaka K, et al: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydro-furyl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann (Jpn J Cancer Res) 70: 209-214, 1979.
14. Fukui Y, Imabayashi N, Nishii M, et al: Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Jpn J Cancer Chemother 7: 2124-2129, 1980.
15. Ota K, Taguchi T. Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333-338, 1988.
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
17. Marunaka T, Umeno Y, Yoshida K, et al: High pressure liquid Chromatographic determination of fturafur [1-(tetrahydro-2-furanyl)-5-fluorouracil and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftrafur. J Pharmacokinetic Sci 69: 1296-1300, 1980.
18. MacDonald JS, Woolley PV, Smythe T, et al: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44: 4247, 1979.
19. Cummingham D, Soukop M, MacArdle CS, et al: Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin, and mitomycin C. Br J Surg 71: 673-676, 1984.
20. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296-2300, 1994.
21. Saltz LB, Leichman C, Young CW, et al: A fixed-ration combination of uracil and fturafur (UFT) with low dose leucovorin. Cancer 75: 782-785, 1995.